Neurizon Therapeutics (ASX:NUZ) has announced the successful registration of its NEURIZON trademark across all major pharmaceutical markets.
The milestone secures brand protection in the United States, European Union, United Kingdom, Australia, and Japan, providing the Company with exclusive rights to use and enforce the NEURIZON name across its core commercial jurisdictions.
For Neurizon, a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative diseases, it marks a strategic foundation for its long-term growth and global ambitions. All trademark registrations cover Class 42 services, encompassing pharmaceutical research and development, clinical trial–related services, and research activities in neurological therapeutics. This scope directly reflects Neurizon’s current clinical focus and its future development plans.
The completion of trademark protection aligns closely with Neurizon’s broader intellectual property strategy, which also includes granted and pending patents for its lead drug candidate, NUZ-001.
Particular importance is attached to successful registration in the United States, which Neurizon identifies as its primary long-term value-creation and commercialisation market. Securing trademark rights in the US provides a strong platform for future operations, including collaboration with clinical trial partners, strategic alliances, potential licensees, and third-party service providers as NUZ-001 progresses through later stages of development.
According to Managing Director and Chief Executive Officer Dr Michael Thurn, the achievement strengthens the Company’s intellectual property framework and enhances strategic flexibility. Combined with its patent portfolio, the trademark protection supports optionality as Neurizon advances NUZ-001, whether through independent commercialisation or partnership-based pathways.